Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS AI-Driven Target Discovery Gains Ground among Japanese Pharma: FRONTEO CEO
December 17, 2025
-
ORGANIZATION Pharma Groups Reiterate “No” to Broader CEA Use, Huge-Seller and Spillover Rules: Joint Statement
December 17, 2025
-
BUSINESS Pfizer Targets Double-Digit Oncology Growth in Japan over Next 5 Years
December 16, 2025
-
REGULATORY Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests
December 15, 2025
-
REGULATORY LDP Tax Panel OKs New 40% R&D Credit for Strategic Technologies
December 12, 2025
-
BUSINESS AG Price Parity Plan Stokes Industry Fears of Patient, Pharmacy Defections
December 12, 2025
-
REGULATORY Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch
December 11, 2025
-
BUSINESS Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
-
BUSINESS Asahi Kasei Pharma Confident of Hitting FY2030 Group Sales Target: President
December 10, 2025
-
BUSINESS LinqMed Builds Radiopharma Plant in Rare Manufacturing Bet for Biotech Startup
December 9, 2025
-
REGULATORY PMDA to Adopt General-Purpose AI in FY2025, Eyes Specialized Tools for Reviews and Safety Work
December 8, 2025
-
REGULATORY Japan Likely to Extend Generic-Name Prescribing Premium to Biologics to Spur Biosimilars
December 8, 2025
-
REGULATORY R&D Tax Credit Draws Broad Calls for Maintenance, Expansion: LDP Meeting
December 8, 2025
-
REGULATORY Forxiga, Zytiga Seen Taking Biggest Hit by PMP Returns in FY2026
December 5, 2025
-
REGULATORY FY2026 Reform Roadmap Keeps Key Drug Pricing Issues on Ice, Snubs Many Industry Requests: Chuikyo
December 4, 2025
-
REGULATORY Average NHI-Market Price Gap Hits Fresh Record Low at 4.8%
December 3, 2025
-
REGULATORY MOF Panel Submits Budget Proposal, Urges Wider CEA Use and More Frequent Re-Pricing
December 3, 2025
-
BUSINESS Lundbeck Japan Plans to Double Workforce by 2028 as It Eyes 3 Drug Approvals
December 2, 2025
-
REGULATORY Japan Allocates 100 Billion-Plus Yen for Drug Innovation, Generic Funds: FY2025 Extra Budget
December 1, 2025
-
BUSINESS Insmed Japan to Double Sales Force with Brensocatib Launch on the Horizon
November 28, 2025
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…